home / stock / fulc / fulc news

FULC News and Press, Fulcrum Therapeutics Inc. From 11/07/23

Stock Information
Company Name: Fulcrum Therapeutics Inc.
Stock Symbol: FULC
Market: NYSE
Website: fulcrumtx.com
Menu
FULC FULC Quote FULC Short FULC News FULC Articles FULC Message Board
Get FULC Alerts

News, Short Squeeze, Breakout and More Instantly...
FULC - Expected US Company Earnings on Tuesday, November 7th, 2023

Weyco Group Inc. (WEYS) is expected to report for Q1 2024 Gladstone Land Corporation (LAND) is expected to report $0.16 for Q3 2023 PlayAGS Inc. (AGS) is expected to report $0.01 for Q3 2023 Ardmore Shipping Corporation (ASC) is expected to report $0.43 for Q3 2023 Sage Therapeuti...
FULC - Expected earnings - Fulcrum Therapeutics Inc.

Fulcrum Therapeutics Inc. (FULC) is expected to report $-0.44 for Q3 2023

FULC - Fulcrum Therapeutics to Host Third Quarter 2023 Financial Results Conference Call and Webcast on Tuesday, November 7, 2023, at 8:00 a.m. ET

CAMBRIDGE, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today a...

FULC - An Updated View On Fulcrum Therapeutics

2023-09-25 14:10:47 ET Summary Fulcrum Therapeutics, Inc. has had some key potential catalysts resolved positively recently. These included the FDA lifted the clinical hold on Fulcrum's sickle-cell disease candidate, allowing the company's Phase 1b trial to move forward. The c...
FULC - Fulcrum Therapeutics to Participate at the Cantor Fitzgerald Global Healthcare Conference

CAMBRIDGE, Mass., Sept. 22, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that management will participate in a fireside c...

FULC - CLNE, QDEL and SOUN are among after hour movers

2023-09-18 17:06:48 ET Gainers: Gain Therapeutics ( NASDAQ: GANX ) +7% . QuidelOrtho  ( QDEL ) +5% . ARS Pharmaceuticals ( SPRY ) +5% . ProFrac Holding  ( ACDC ) +5% . Clean Energy Fuels  ( CLNE ) +4% . L...

FULC - Wave of FDA Fast Track Designations Highlight Biotech Momentum Carrying into 2023

2023-09-13 09:00:30 ET FN Media Group Presents USA News Group News Commentary Vancouver, BC – September 13, 2023 – USA News Group –  Sufferers of many different ailments saw reason to grow their hope in 2022 when the US Food and Drug Administr...
FULC - GRAB, DHC and ADPT are among after hour movers

2023-09-12 17:27:39 ET Gainers: Rocket Pharmaceuticals ( RCKT ) +30% . Alset Capital Acquisition  ( ACAX ) +14% . Veeco Instruments  ( VECO ) +7% . InnovAge Holding  ( INNV ) +4% . Fulcrum Therapeutics ( FULC ) +4% ...

FULC - Fulcrum's Balance: Between Promise And Uncertainty

2023-09-11 12:00:00 ET Summary Fulcrum Therapeutics focuses on rare genetic diseases with losmapimod in Phase 3 trial; stock is down 56% since February. Fulcrum's financial health is strong with $278.2M in cash; monthly cash burn approximates $7.484M, supporting operations till mi...

FULC - Fulcrum Announces Completion of Enrollment in the Phase 3 REACH Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)

CAMBRIDGE, Mass., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that it has completed enrollment in REACH, a Pha...
Previous 10 Next 10